KALV
Price
$14.58
Change
-$1.02 (-6.54%)
Updated
Jul 25 closing price
Capitalization
728.33M
40 days until earnings call
PHMMF
Price
$92.57
Change
-$1.24 (-1.32%)
Updated
Jun 23 closing price
Capitalization
1.68B
Interact to see
Advertisement

KALV vs PHMMF

Header iconKALV vs PHMMF Comparison
Open Charts KALV vs PHMMFBanner chart's image
KalVista Pharmaceuticals
Price$14.58
Change-$1.02 (-6.54%)
Volume$1.02M
Capitalization728.33M
Pharma Mar SA
Price$92.57
Change-$1.24 (-1.32%)
Volume$2.69K
Capitalization1.68B
KALV vs PHMMF Comparison Chart in %
Loading...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHMMF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KALV vs. PHMMF commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KALV is a Hold and PHMMF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (KALV: $14.58 vs. PHMMF: $92.57)
Brand notoriety: KALV and PHMMF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KALV: 78% vs. PHMMF: 53%
Market capitalization -- KALV: $728.33M vs. PHMMF: $1.68B
KALV [@Biotechnology] is valued at $728.33M. PHMMF’s [@Biotechnology] market capitalization is $1.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KALV’s FA Score shows that 0 FA rating(s) are green whilePHMMF’s FA Score has 1 green FA rating(s).

  • KALV’s FA Score: 0 green, 5 red.
  • PHMMF’s FA Score: 1 green, 4 red.
According to our system of comparison, PHMMF is a better buy in the long-term than KALV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KALV’s TA Score shows that 4 TA indicator(s) are bullish while PHMMF’s TA Score has 5 bullish TA indicator(s).

  • KALV’s TA Score: 4 bullish, 5 bearish.
  • PHMMF’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PHMMF is a better buy in the short-term than KALV.

Price Growth

KALV (@Biotechnology) experienced а -5.26% price change this week, while PHMMF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

KALV is expected to report earnings on Sep 04, 2025.

PHMMF is expected to report earnings on Apr 24, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHMMF($1.68B) has a higher market cap than KALV($728M). KALV YTD gains are higher at: 72.137 vs. PHMMF (14.185). PHMMF has higher annual earnings (EBITDA): 22.9M vs. KALV (-173.33M). KALV has more cash in the bank: 221M vs. PHMMF (141M). KALV has less debt than PHMMF: KALV (6.31M) vs PHMMF (51.9M). PHMMF has higher revenues than KALV: PHMMF (176M) vs KALV (0).
KALVPHMMFKALV / PHMMF
Capitalization728M1.68B43%
EBITDA-173.33M22.9M-757%
Gain YTD72.13714.185509%
P/E RatioN/A69.56-
Revenue0176M-
Total Cash221M141M157%
Total Debt6.31M51.9M12%
FUNDAMENTALS RATINGS
KALV vs PHMMF: Fundamental Ratings
KALV
PHMMF
OUTLOOK RATING
1..100
1549
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
3
Undervalued
PROFIT vs RISK RATING
1..100
93100
SMR RATING
1..100
9868
PRICE GROWTH RATING
1..100
3840
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PHMMF's Valuation (3) in the null industry is somewhat better than the same rating for KALV (61) in the Pharmaceuticals Other industry. This means that PHMMF’s stock grew somewhat faster than KALV’s over the last 12 months.

KALV's Profit vs Risk Rating (93) in the Pharmaceuticals Other industry is in the same range as PHMMF (100) in the null industry. This means that KALV’s stock grew similarly to PHMMF’s over the last 12 months.

PHMMF's SMR Rating (68) in the null industry is in the same range as KALV (98) in the Pharmaceuticals Other industry. This means that PHMMF’s stock grew similarly to KALV’s over the last 12 months.

KALV's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as PHMMF (40) in the null industry. This means that KALV’s stock grew similarly to PHMMF’s over the last 12 months.

PHMMF's P/E Growth Rating (98) in the null industry is in the same range as KALV (100) in the Pharmaceuticals Other industry. This means that PHMMF’s stock grew similarly to KALV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KALVPHMMF
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 3 days ago
52%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
46%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
41%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
51%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
45%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 12 days ago
87%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 4 days ago
67%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHMMF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPSPX24.670.05
+0.20%
NYLI Epoch Global Equity Yield Class A
ALCCX19.27N/A
N/A
Alger Capital Appreciation C
IICHX11.66N/A
N/A
AMF Large Cap Equity H
VRTIX345.88N/A
N/A
Vanguard Russell 2000 Index I
VGHRX51.31N/A
N/A
Voya Global High Dividend Low Vol R6

PHMMF and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHMMF has been loosely correlated with DRUG. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if PHMMF jumps, then DRUG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHMMF
1D Price
Change %
PHMMF100%
N/A
DRUG - PHMMF
42%
Loosely correlated
+10.83%
CSCI - PHMMF
22%
Poorly correlated
-1.52%
KALV - PHMMF
21%
Poorly correlated
-6.54%
ACAD - PHMMF
21%
Poorly correlated
+0.87%
AVCTF - PHMMF
20%
Poorly correlated
+20.54%
More